GlassScriptPhysician profile
Lucas J Beerepoot
NPI 1093906455
$643.45
in general payments reported to CMS, 2019-2025
13 companies · $30.58 in 2025
The $30.58 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $69.11 · 2021: $28.11 · 2024: $13.29 · 2025: $30.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $43.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $43.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $227.81 | 2019 | |
| Amgen INC. | $100.68 | 2019 | |
| Lilly USA, LLC | $86.25 | 2019 | |
| Emd Serono, INC. | $42.92 | 2019-2020 | |
| Abbvie INC. | $40.18 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $33.46 | 2019 | |
| Allergan, INC. | $20.62 | 2020 | |
| Zyla Life Sciences, INC. | $19.87 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.04 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.76 | 2025 | Rexulti |
| Greenwich Biosciences, INC. | $14.40 | 2019 | |
| Livanova USA, INC. | $13.43 | 2020 | |
| Acadia Pharmaceuticals INC | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucas Beerepoot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.